Global Premenstrual Dysphoric Disorder Market, By Treatment (Antidepressants, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Analgesics, Hormone Therapy, Exercise, Diet, Others), Diagnosis (Physical Examination, Others), Symptoms (Depression, Intense Anger, Mood Swings, Irritability, No interest in your usual activities, Anxiety, Trouble Concentrating, Appetite Changes, Feeling out of control, Fatigue, Cramps and Bloating, Tension, Headache, Insomnia, Joint or Muscle Pain, Breast Tenderness, Hot Flashes, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Premenstrual Dysphoric Disorder Market
Premenstrual dysphoric disorder market is expected to gain market growth in the forecast period of 2021-2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6.30% in the above mentioned forecast period.
PMDD is a condition similar to PMS that occurs a week or two before your period begins as hormone levels drop after ovulation. PMDD is associated with more severe symptoms than PMS, such as depression, irritability, and tension. PMDD has an unknown aetiology. It could be a reaction to the usual hormonal changes that occur during each menstrual cycle. The hormone changes can produce a serotonin deficiency. Serotonin is a chemical found naturally in the brain and intestines that narrows blood vessels and can impact mood and induce physical symptoms.
The rise in premenstrual dysphoric disorder and rising healthcare expenditure are the major factors influencing the market growth rate. Furthermore, advancement in medical technology, growing government funding and increasing initiatives by public and private organizations to spread awareness about the disease and its preventive options are the factors that will expand the premenstrual dysphoric disorder market. Other factors including changing lifestyle, poor hygiene, alcohol abuse and lack of exercise will positively impact the market growth rate.
Rise in the research and development activities and emerging new markets will provide beneficial opportunities for the premenstrual dysphoric disorder market in the forecast period of 2021-2028.
However, the high cost associated with the treatment and side effects of medications are the factors that will hinder the market growth. Lack of awareness will further challenge the premenstrual dysphoric disorder market in the forecast period mentioned above.
This premenstrual dysphoric disorder market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the premenstrual dysphoric disorder market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Premenstrual Dysphoric Disorder Market Scope and Market Size
The premenstrual dysphoric disorder market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of treatment, the premenstrual dysphoric disorder market is segmented into antidepressants, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, hormone therapy, exercise, diet and others.
- On the basis of diagnosis, the premenstrual dysphoric disorder market is segmented into physical examination and others.
- On the basis of symptoms, the premenstrual dysphoric disorder market is segmented into depression, intense anger, mood swings, irritability, no interest in your usual activities, anxiety, trouble concentrating, appetite changes, feeling out of control, fatigue, cramps and bloating, tension, headache, insomnia, joint or muscle pain, breast tenderness, hot flashes and others.
- On the basis of dosage, the premenstrual dysphoric disorder market is segmented into tablet, injection and others.
- On the basis of route of administration, the premenstrual dysphoric disorder market is segmented into oral, intravenous and others.
- On the basis of end-users, the premenstrual dysphoric disorder market is segmented into clinic, hospital and others.
The premenstrual dysphoric disorder market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Premenstrual Dysphoric Disorder Market Country Level Analysis
Premenstrual dysphoric disorder market is analyzed and market size information is provided by the country, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the premenstrual dysphoric disorder market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the premenstrual dysphoric disorder market due to the rising awareness about diseases, health related problems arising due to changing lifestyle and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the promptly expanding infrastructure of healthcare sector and growing awareness in this region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Premenstrual dysphoric disorder market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Premenstrual Dysphoric Disorder Market Share Analysis
Premenstrual dysphoric disorder market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to premenstrual dysphoric disorder market research.
The major players covered in the premenstrual dysphoric disorder market report are Pfizer Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Novartis AG, Cipla Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca, Johnson & Johnson Private Limited, Sanofi, Bayer AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Mylan N.V., Allergan, Takeda Pharmaceutical Company Limited., Sumitomo Dainippon Pharma Co., Ltd., AbbVie Inc., and Dr. Reddy’s Laboratories Ltd., Lupin, Bausch Health Companies Inc., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.